1Grahek D,Monutravers F,Kerrou K,et al.[18F]FDG in recurrent breast cancer:diagnostic performances,clinical impact and relevance of induced changes in management[J].Eur J Nucl Med Mol Imaging,2004,31(2):179-188.
2Singletary SE,Allred C,Ashley P,et al.Revision of the American Joint Committee on Cancer staging system for breast cancer[J].J Clin Oncol,2002,20 (17):3628-3636.
3Rousseau C,Devillers A,Sagan C,et al.Monitoring early response to neoadjuvant chemotherapy in stage Ⅱ and III breast cancer by[18F]Fluorodeoxyglucose positron emission tomography[J].J Clin Oncol,2006,24(34):5366-5372.
4Patz EF Jr,Lowe VJ,Hoffman JM,et al.Focal pulmonary abnormalities:evaluation with F-18 flu-orodeoxyglucose PET scanning[J].Radiology,1993,188 (2):487-490.
5Hsueh WA,Kesner AL,Gangloff A,et al.Predicting chemotherapy response to paclitaxel with 18F-Fluropaclitaxel and PET[J].J Nucl Med,2006,47(12):1995-1999.
7Lyman GH,Giuliano AE,Somerfield MR,et al.American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer[J].J Clin Oncol,2005,23 (30):7703-7720.
8Wahl RL,Siegel BA,Coleman RE,et al.Prospective multicenter study of axillary nodal staging by positron emission tomog-raphy in breast cancer:a report of the staging breast cancer with PET Study Group[J].J Clin Oncol,2004,22(2):277-285.
9Dose J,Bleckmann C,Bachmann S,et al.Comparison of fluorodeoxyglucose positron emis-sion tomography and "conventional diagno stic procedures" for the detection of distant metastases in breast cancer patients[J].Nucl Med Common,2002,23(9):857-864.
10Biersack HJ,Bender H,Palmedo H.FDG-PET in monitoring therapy of breast cancer[J].Eur J Nucl Med Mol Imaging,2004,31(Suppl 1):S112-S117.
